Caladrius Biosciences Inc.'s worldwide, three-pronged cell-therapy technology deal through a subsidiary with Tokyo-based Hitachi Chemical Co. Ltd. not only brings money aboard but also could help snag a partner in Japan for the firm's CD34 ischemic-repair bid, communications director Eric Powers told BioWorld Today.
